Pyxis Oncology (PYXS) Total Non-Current Liabilities (2020 - 2024)

Pyxis Oncology (PYXS) has reported Total Non-Current Liabilities for 5 consecutive years, with $41.6 million the latest figure, recorded in Q3 2024.

• On a quarterly basis, Total Non-Current Liabilities fell 14.6% year-over-year to $41.6 million in Q3 2024; TTM through Sep 2024 was $41.6 million, a 14.6% decrease from a year earlier, with the FY2023 full-year figure at $48.0 million, down 5.01% from the prior year.
• Total Non-Current Liabilities was $41.6 million for Q3 2024 at Pyxis Oncology, up from $38.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $50.6 million in Q4 2022 and troughed at $3.9 million in Q4 2020.
• A 5-year average of $33.2 million and a median of $35.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 385.42% in 2021 and slumped 58.84% in 2022, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $3.9 million in 2020, then jumped by 385.42% to $18.7 million in 2021, then jumped by 170.23% to $50.6 million in 2022, then retreated by 5.01% to $48.0 million in 2023, then slipped by 13.31% to $41.6 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $41.6 million (Q3 2024), $38.6 million (Q2 2024), and $36.1 million (Q1 2024), per Business Quant data.